Novel pathogenic mechanism suggested by ex vivo analysis of MCT8 (SLC16A2) mutations
Author
dc.contributor.author
Visser, W. Edward
Author
dc.contributor.author
Jansen, Jurgen
Author
dc.contributor.author
Friesema, Edith C.H.
Author
dc.contributor.author
Kester, Monique H.A.
Author
dc.contributor.author
Mancilla, Edna
Author
dc.contributor.author
Lundgren, Johan
Author
dc.contributor.author
Van Der Knaap, Marjo S.
Author
dc.contributor.author
Lunsing, Roelineke J.
Author
dc.contributor.author
Brouwer, Oebele F.
Author
dc.contributor.author
Visser, Theo J.
Admission date
dc.date.accessioned
2019-03-11T12:56:49Z
Available date
dc.date.available
2019-03-11T12:56:49Z
Publication date
dc.date.issued
2009
Cita de ítem
dc.identifier.citation
Human Mutation, Volumen 30, Issue 1, 2018, Pages 29-38
Identifier
dc.identifier.issn
10597794
Identifier
dc.identifier.other
10.1002/humu.20808
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164674
Abstract
dc.description.abstract
Monocarboxylate transporter 8 (MCT8; approved symbol SLC16A2) facilitates cellular uptake and efflux of 3,3′,5-triiodothyronine (T3). Mutations in MCT8 are associated with severe psychomotor retardation, high serum T3 and low 3,3′,5′-triiodothyronine (rT3) levels. Here we report three novel MCT8 mutations. Two subjects with the F501del mutation have mild psychomotor retardation with slightly elevated T3 and normal rT3 levels. T3 uptake was mildly affected in F501del fibroblasts and strongly decreased in fibroblasts from other MCT8 patients, while T3 efflux was always strongly reduced. Moreover, type 3 deiodinase activity was highly elevated in F501del fibroblasts, whereas it was reduced in fibroblasts from other MCT8 patients, probably reflecting parallel variation in cellular T3 content. Additionally, T3-responsive genes were markedly upregulated by T3 treatment in F501del fibroblasts but not in fibroblasts with other MCT8 mutations. In conclusion, mutations in MCT8 result in a decrea